Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 16:47:45 ON 02 DEC 2009

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 16:47:57 ON 02 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    1 DEC 2009  HIGHEST RN 1194901-26-2
DICTIONARY FILE UPDATES:   1 DEC 2009  HIGHEST RN 1194901-26-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s CHIR 258/cn
L1            1 CHIR 258/CN

=> d l1

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   692737-80-7  REGISTRY
ED   Entered STN:  14 Jun 2004
CN   Propanoic acid, 2-hydroxy-, compd. with
     4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-
     quinolinone (1:1)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Propanoic acid, 2-hydroxy-, compd. with
     4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-
     quinolinone (1:1) (9CI)
OTHER NAMES:
CN   CHIR 258
CN   Dovitinib lactate
CN   TKI 258
DR   1000873-96-0
MF   C21 H21 F N6 O . C3 H6 O3
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

     CM   1

     CRN  405169-16-6
     CMF  C21 H21 F N6 O
```



CM 2

CRN 50-21-5
CMF C3 H6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 405169-16-6/crn
L2 31 405169-16-6/CRN

=> d l2

L2 ANSWER 1 OF 31 REGISTRY COPYRIGHT 2009 ACS on STN
RN 1187448-25-4 REGISTRY
ED Entered STN: 06 Oct 2009
CN INDEX NAME NOT YET ASSIGNED
MF C21 H21 F N6 O . x C3 H7 N O . C3 H6 O3
SR CA
LC STN Files: CA, CAPLUS

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 68-12-2
CMF C3 H7 N O



CM 3

CRN 50-21-5
CMF C3 H6 O3



1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d his

(FILE 'HOME' ENTERED AT 16:47:45 ON 02 DEC 2009)

FILE 'REGISTRY' ENTERED AT 16:47:57 ON 02 DEC 2009
L1 1 S CHIR 258/CN
L2 31 S 405169-16-6/CRN

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 10.41 10.63

FILE 'CAPLUS' ENTERED AT 16:49:05 ON 02 DEC 2009

FILE COVERS 1907 - 2 Dec 2009 VOL 151 ISS 23
FILE LAST UPDATED: 1 Dec 2009 (20091201/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l2
L3          64 L2

=> s l3 and ad<20031107
       4775475 AD<20031107
                  (AD<20031107)
L4           2 L3 AND AD<20031107

=> d l4 1-2 ibib abs
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1242789 CAPLUS
DOCUMENT NUMBER: 143:477969
TITLE: Preparation of benzimidazole quinolinones for inhibiting FGFR3 and treating multiple myeloma
INVENTOR(S): Cai, Shaopei; Chou, Joyce; Harwood, Eric; Heise, Carla C.; Machajewski, Timothy D.; Ryckman, David; Shang, Xiao; Wiesmann, Marion; Zhu, Shuguang
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 239 pp., Cont.-in-part of U.S. Ser. No. 644,055.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20050261307	A1	20051124	US 2004-983174	20041105	
US 20040092535	A1	20040513	US 2003-644055	20030819	<--
US 7470709	B2	20081230			
CN 1692112	A	20051102	CN 2003-824565	20030819	<--
US 20050203101	A1	20050915	US 2004-839793	20040505	
ZA 2006003598	A	20080430	ZA 2006-3598	20060505	
US 20090281100	A1	20091112	US 2008-317493	20081223	
US 20090181979	A1	20090716	US 2009-398130	20090304	

PRIORITY APPLN. INFO.:

US 2002-405729P	P	20020823
US 2002-426107P	P	20021113
US 2002-426226P	P	20021113
US 2002-426282P	P	20021113
US 2002-428210P	P	20021121
US 2003-460327P	P	20030403
US 2003-460328P	P	20030403
US 2003-460493P	P	20030403
US 2003-478916P	P	20030616
US 2003-484048P	P	20030701
US 2003-644055	A2	20030819
US 2003-517915P	P	20031107
US 2003-526425P	P	20031202
US 2003-526426P	P	20031202
US 2004-546017P	P	20040219
US 2004-982543	B1	20041105

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 143:477969
GI



I



II

AB The title compds. I [A, B, C, and D = C, N; R1-R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl; R5-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H], useful for inhibiting fibroblast growth factor receptor 3 or treating a biol. condition mediated by fibroblast growth factor receptor 3, were prepared E.g., a multi-step synthesis of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one (II), starting from 5-chloro-2-nitroaniline and 1-methylpiperazine, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM. The mentioned above compound II was tested in various tests and showed significant antiproliferative activity. II inhibited FGFR3 receptor phosphorylation and ERK phosphorylation in multiple myeloma cell lines with activating FGFR3 mutations.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1223876 CAPLUS
DOCUMENT NUMBER: 143:477966
TITLE: Preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer
INVENTOR(S): Gesner, Thomas G.; Barsanti, Paul A.; Harrison, Stephen D.; Ni, Zhi-Jie; Brammeier, Nathan M.; Zhou, Yasheen; Le, Vincent P.
PATENT ASSIGNEE(S): Chiron Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 249 pp., Cont.-in-part of U.S. Ser. No. 644,055.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050256157	A1	20051117	US 2005-41191		20050121	
US 20040092535	A1	20040513	US 2003-644055		20030819	<--
US 7470709	B2	20081230				
CN 1692112	A	20051102	CN 2003-824565		20030819	<--
US 20050203101	A1	20050915	US 2004-839793		20040505	
US 20090281100	A1	20091112	US 2008-317493		20081223	
PRIORITY APPLN. INFO.:			US 2002-405729P	P	20020823	
			US 2002-426107P	P	20021113	
			US 2002-426226P	P	20021113	
			US 2002-426282P	P	20021113	
			US 2002-428210P	P	20021121	
			US 2003-460327P	P	20030403	
			US 2003-460328P	P	20030403	
			US 2003-460493P	P	20030403	
			US 2003-478916P	P	20030616	
			US 2003-484048P	P	20030701	
			US 2003-644055	A2	20030819	
			US 2004-538984P	P	20040123	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:477966; MARPAT 143:477966
GI



I

AB The title compds. [I; A, B, C, D = C, N; R1 = H, halo, CN, NO2, etc.; R2, R3 = H, halo, NO2, CN, etc.; R4 = H, (un)substituted alkyl; R5, R8 = H, (un)substituted alkyl, alkenyl, heterocyclyl; or R5 may be absent if A = N; or R8 may be absent if D = N; R6, R7 = H, halo, NO2, CN, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or R9 and R10 join together to form one or more rings, each having 5-7 members], useful for inhibiting checkpoint kinase 1, inducing cell cycle progression, and increasing apoptosis in cells, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The compds. I were tested against various kinases. Two of the prepared compds. I, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2-(1H)-one and 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-4-[(piperidin-2-ylmethyl)amino]quinolin-2(1H)-one, were found to be potent inhibitors of CHK1 with IC50 of 0.32 nM and 0.63 nM, resp. The majority of the

exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM. The compds. I may be used to prepare pharmaceutical compns. and may be used in conjunction with DNA damaging agents.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 16:47:45 ON 02 DEC 2009)

FILE 'REGISTRY' ENTERED AT 16:47:57 ON 02 DEC 2009
L1 1 S CHIR 258/CN
L2 31 S 405169-16-6/CRN

FILE 'CAPLUS' ENTERED AT 16:49:05 ON 02 DEC 2009
L3 64 S L2
L4 2 S L3 AND AD<20031107

=> d l1
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 692737-80-7 REGISTRY
ED Entered STN: 14 Jun 2004
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (9CI)
OTHER NAMES:
CN CHIR 258
CN Dovitinib lactate
CN TKI 258
DR 1000873-96-0
MF C21 H21 F N6 O . C3 H6 O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s 1000873-96-0/dr
'DR' IS NOT A VALID FIELD CODE
L5 0 1000873-96-0/DR

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.50	22.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.64

FILE 'REGISTRY' ENTERED AT 16:50:24 ON 02 DEC 2009

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 DEC 2009 HIGHEST RN 1194901-26-2
DICTIONARY FILE UPDATES: 1 DEC 2009 HIGHEST RN 1194901-26-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> S 1000873-96-0/RN

L6 1 1000873-96-0/RN

=> SET NOTICE 1 DISPLAY

NOTICE SET TO 1 U.S. DOLLAR FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=> D L6 SQIDE 1-

YOU HAVE REQUESTED DATA FROM 1 ANSWERS - CONTINUE? Y/(N):y
THE ESTIMATED COST FOR THIS REQUEST IS 6.85 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 692737-80-7 REGISTRY
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[5-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone (1:1) (9CI)
OTHER NAMES:
CN CHIR 258
CN Dovitinib lactate
CN TKI 258
DR 1000873-96-0
MF C21 H21 F N6 O . C3 H6 O3
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL
DT.CA CAplus document type: Conference; Journal; Patent
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

CM 1

CRN 405169-16-6
CMF C21 H21 F N6 O



CM 2

CRN 50-21-5
CMF C3 H6 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

61 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
63 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> SET NOTICE LOGIN DISPLAY

NOTICE SET TO OFF FOR DISPLAY COMMAND
SET COMMAND COMPLETED

=>

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.53	24.93

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-1.64

FILE 'CAPLUS' ENTERED AT 16:50:46 ON 02 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Dec 2009 VOL 151 ISS 23
FILE LAST UPDATED: 1 Dec 2009 (20091201/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l6
L7   63 L6

=> s l7 and ad<20031107
       4775475 AD<20031107
                  (AD<20031107)
L8   2 L7 AND AD<20031107

=> d l8 1-2 ibib abs

L8   ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1242789 CAPLUS
DOCUMENT NUMBER: 143:477969
TITLE: Preparation of benzimidazole quinolinones for
                         inhibiting FGFR3 and treating multiple myeloma
INVENTOR(S):   Cai, Shaopei; Chou, Joyce; Harwood, Eric; Heise, Carla
                         C.; Machajewski, Timothy D.; Ryckman, David; Shang,
                         Xiao; Wiesmann, Marion; Zhu, Shuguang
PATENT ASSIGNEE(S):   Chiron Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 239 pp., Cont.-in-part of U.S.
                         Ser. No. 644,055.
                         CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050261307	A1	20051124	US 2004-983174		20041105	
US 20040092535	A1	20040513	US 2003-644055		20030819	<--
US 7470709	B2	20081230				
CN 1692112	A	20051102	CN 2003-824565		20030819	<--
US 20050203101	A1	20050915	US 2004-839793		20040505	
ZA 2006003598	A	20080430	ZA 2006-3598		20060505	
US 20090281100	A1	20091112	US 2008-317493		20081223	
US 20090181979	A1	20090716	US 2009-398130		20090304	
PRIORITY APPLN. INFO.:			US 2002-405729P	P	20020823	
			US 2002-426107P	P	20021113	
			US 2002-426226P	P	20021113	
			US 2002-426282P	P	20021113	
			US 2002-428210P	P	20021121	
			US 2003-460327P	P	20030403	
			US 2003-460328P	P	20030403	
			US 2003-460493P	P	20030403	
			US 2003-478916P	P	20030616	

US 2003-484048P	P	20030701
US 2003-644055	A2	20030819
US 2003-517915P	P	20031107
US 2003-526425P	P	20031202
US 2003-526426P	P	20031202
US 2004-546017P	P	20040219
US 2004-982543	B1	20041105

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 143:477969
GI



I



II

AB The title compds. I [A, B, C, and D = C, N; R1-R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl; R5-R8 = H, halo, CN, NO2, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H], useful for inhibiting fibroblast growth factor receptor 3 or treating a biol. condition mediated by fibroblast growth factor receptor 3, were prepared E.g., a multi-step synthesis of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one (II), starting from 5-chloro-2-nitroaniline and 1-methylpiperazine, was given. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM. The mentioned above compound II was tested in various tests and showed significant antiproliferative activity. II inhibited FGFR3 receptor phosphorylation and ERK phosphorylation in multiple myeloma cell lines with activating FGFR3 mutations.
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1223876 CAPLUS

DOCUMENT NUMBER: 143:477966
TITLE: Preparation of benzimidazole quinolinones for inhibiting a checkpoint kinase 1 and their use in combination therapy for cancer
INVENTOR(S): Gesner, Thomas G.; Barsanti, Paul A.; Harrison, Stephen D.; Ni, Zhi-Jie; Brammeier, Nathan M.; Zhou, Yasheen; Le, Vincent P.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 249 pp., Cont.-in-part of U.S. Ser. No. 644,055.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20050256157	A1	20051117	US 2005-41191		20050121	
US 20040092535	A1	20040513	US 2003-644055		20030819	<--
US 7470709	B2	20081230				
CN 1692112	A	20051102	CN 2003-824565		20030819	<--
US 20050203101	A1	20050915	US 2004-839793		20040505	
US 20090281100	A1	20091112	US 2008-317493		20081223	
PRIORITY APPLN. INFO.:			US 2002-405729P	P	20020823	
			US 2002-426107P	P	20021113	
			US 2002-426226P	P	20021113	
			US 2002-426282P	P	20021113	
			US 2002-428210P	P	20021121	
			US 2003-460327P	P	20030403	
			US 2003-460328P	P	20030403	
			US 2003-460493P	P	20030403	
			US 2003-478916P	P	20030616	
			US 2003-484048P	P	20030701	
			US 2003-644055	A2	20030819	
			US 2004-538984P	P	20040123	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:477966; MARPAT 143:477966
GI



I

AB The title compds. [I; A, B, C, D = C, N; R1 = H, halo, CN, NO2, etc.; R2, R3 = H, halo, NO2, CN, etc.; R4 = H, (un)substituted alkyl; R5, R8 = H, (un)substituted alkyl, alkenyl, heterocyclyl; or R5 may be absent if A = N; or R8 may be absent if D = N; R6, R7 = H, halo, NO2, CN, etc.; R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H; or R9 and R10 join together to form one or more rings, each having 5-7 members], useful for inhibiting checkpoint kinase 1, inducing cell cycle progression, and increasing

apoptosis in cells, were prepared E.g., a multi-step synthesis of 4-amino-3-(benzimidazol-2-yl)-6-(4-methylpiperazinyl)hydroquinolin-2-one, was given. The compds. I were tested against various kinases. Two of the prepared compds. I, 4-[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1H-benzimidazol-2-yl)-6-chloroquinolin-2-(1H)-one and 6-chloro-3-[5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-4-[(piperidin-2-ylmethyl)amino]quinolin-2(1H)-one, were found to be potent inhibitors of CHK1 with IC50 of 0.32 nM and 0.63 nM, resp. The majority of the exemplary compds. I displayed an IC50 of less than 10 μM with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, Cdk4, MEK1, NEK-2, CHK2, CK1ε, Raf, Fyn, Lck, Rsk2, PAR-1, c-Kit, c-ABL, p60src, FGFR3, FLT-3, PDGFRα, and PDGFRβ. In addition, many of the exemplary compds. exhibited IC50 values in the nM range and show potent activity with respect to VEGFR1, VEGFR2, VEGFR3, FGFR1, FGFR3, c-Kit, c-ABL, FLT-3, CHK1, Cdc2, GSK-3, NEK-2, Cdk2, MEK1, CHK2, Fyn, Lck, Rsk2, PAR-1, PDGFRα, and PDGFRβ with IC50 values of less than 1 μM. The compds. I may be used to prepare pharmaceutical compns. and may be used in conjunction with DNA damaging agents.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

=> d his

(FILE 'HOME' ENTERED AT 16:47:45 ON 02 DEC 2009)

FILE 'REGISTRY' ENTERED AT 16:47:57 ON 02 DEC 2009
L1 1 S CHIR 258/CN
L2 31 S 405169-16-6/CRN

FILE 'CAPLUS' ENTERED AT 16:49:05 ON 02 DEC 2009
L3 64 S L2
L4 2 S L3 AND AD<20031107

FILE 'REGISTRY' ENTERED AT 16:49:48 ON 02 DEC 2009

FILE 'CAPLUS' ENTERED AT 16:49:49 ON 02 DEC 2009
L5 0 S 1000873-96-0/DR

FILE 'REGISTRY' ENTERED AT 16:50:24 ON 02 DEC 2009
L6 1 S 1000873-96-0/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 16:50:46 ON 02 DEC 2009
L7 63 S L6
L8 2 S L7 AND AD<20031107

=> file medline embase biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	9.24	34.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.64	-3.28

FILE 'MEDLINE' ENTERED AT 16:51:43 ON 02 DEC 2009

FILE 'EMBASE' ENTERED AT 16:51:43 ON 02 DEC 2009

```
FILE 'BIOSIS' ENTERED AT 16:51:43 ON 02 DEC 2009
Copyright (c) 2009 The Thomson Corporation

=> s l2
L9           0 L2

=> s l2<chem>

   SmartSELECT INITIATED
New TRANSFER and ANALYZE Commands Now Available
See HELP TRANSFER and HELP ANALYZE for Details


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       5.07      39.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.28

FILE 'REGISTRY' ENTERED AT 16:51:51 ON 02 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

SET SMARTSELECT ON
SET COMMAND COMPLETED

SEL L2 1- CHEM
L10          SEL L2 1- CHEM :      36 TERMS

SET SMARTSELECT OFF
SET COMMAND COMPLETED


COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      15.08      54.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.28

FILE 'MEDLINE' ENTERED AT 16:51:53 ON 02 DEC 2009

FILE 'EMBASE' ENTERED AT 16:51:53 ON 02 DEC 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 16:51:53 ON 02 DEC 2009
Copyright (c) 2009 The Thomson Corporation

S L10
L11        107 L10

=> s l11 and (?cancer? or ?tumor? or ?tumour? or ?neoplasm?)
L12          93 L11 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)

=> dup rem l12
PROCESSING COMPLETED FOR L12
L13           87 DUP REM L12 (6 DUPLICATES REMOVED)
```

```
=> s l13 and pd<20031107
   1 FILES SEARCHED...
L14          5 L13 AND PD<20031107

=> d l14 1-5 ibib abs

L14  ANSWER 1 OF 5  EMBASE  COPYRIGHT (c) 2009 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:   2003481481  EMBASE
TITLE:              The impact of anti-angiogenic agents on cancer
                    therapy.
AUTHOR:             Marme, Dieter (correspondence)
CORPORATE SOURCE:   Tumor Biology Center, Institute of Molecular Oncology,
                    Breisacherstrasse 117, 79106 Freiburg, Germany. marme@tumor
                    bio.uni-freiburg.de
SOURCE:             Journal of Cancer Research and Clinical Oncology, (Nov
                    2003) Vol. 129, No. 11, pp. 607-620.
                    Refs: 89
                    ISSN: 0171-5216  CODEN: JCROD7
COUNTRY:            Germany
DOCUMENT TYPE:      Journal; General Review; (Review)
FILE SEGMENT:       016     Cancer
                    030     Clinical and Experimental Pharmacology
                    037     Drug Literature Index
                    038     Adverse Reactions Titles
LANGUAGE:           English
ENTRY DATE:         Entered STN: 29 Dec 2003
                    Last Updated on STN: 29 Dec 2003

L14  ANSWER 2 OF 5  EMBASE  COPYRIGHT (c) 2009 Elsevier B.V. All rights
     reserved on STN
ACCESSION NUMBER:   2003373828  EMBASE
TITLE:              Anti-cancer drug discovery and development
                    summit.
AUTHOR:             Blakey, David C. (correspondence)
CORPORATE SOURCE:   AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10
                    4TF, United Kingdom. david.blakey@astrazeneca.com
SOURCE:             Expert Opinion on Investigational Drugs, (1 Sep
                    2003) Vol. 12, No. 9, pp. 1577-1582.
                    Refs: 15
                    ISSN: 1354-3784  CODEN: EOIDER
COUNTRY:            United Kingdom
DOCUMENT TYPE:      Journal; Conference Article; (Conference paper)
FILE SEGMENT:       016     Cancer
                    030     Clinical and Experimental Pharmacology
                    037     Drug Literature Index
                    038     Adverse Reactions Titles
LANGUAGE:           English
SUMMARY LANGUAGE:   English
ENTRY DATE:         Entered STN: 2 Oct 2003
                    Last Updated on STN: 2 Oct 2003
AB   The 5th Annual Anti-Cancer Drug Discovery and Development Summit
     brought together an international group of academic and industry
     scientists to discuss recent therapeutic developments in the field of
     oncology.  The focus of the meeting was novel targeted approaches, i.e.,
     those agents directed against targets that are overexpressed or overactive
     in tumour cells.  It was acknowledged that cytotoxic agents will
     continue to play a key role in the treatment of cancer and new
     developments in this area were also discussed.  With over 400
     anticancer drugs in clinical development and a number of recent
     registrations, there is great optimism that significant therapeutic
     advances can be made.
```

L14 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003363876 EMBASE
TITLE: American Association for Cancer Research - 9th Annual Meeting: Investigating drugs: 11-14 July 2003, Washington, DC, USA.
AUTHOR: Mackay, Janie (correspondence); Williams, Laura
CORPORATE SOURCE: Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4JE, United Kingdom. laura.williams@current-drugs.com; janie.mackay@current-drugs.com
SOURCE: IDrugs, (1 Aug 2003) Vol. 6, No. 8, pp. 736-738. ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 016 Cancer
030 Clinical and Experimental Pharmacology
036 Health Policy, Economics and Management
037 Drug Literature Index
038 Adverse Reactions Titles
052 Toxicology
LANGUAGE: English
ENTRY DATE: Entered STN: 25 Sep 2003
Last Updated on STN: 25 Sep 2003

L14 ANSWER 4 OF 5 EMBASE COPYRIGHT (c) 2009 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2003276961 EMBASE
TITLE: Kinases - SMi Conference 9-10 April 2003, London, UK.
AUTHOR: Harrison, Ruth (correspondence)
CORPORATE SOURCE: Thomson Current Drugs, Middlesex House, 34-42 Cleveland Street, London W1T 4LB, United Kingdom. ruth.harrison@current-drugs.com
SOURCE: IDrugs, (1 Jun 2003) Vol. 6, No. 6, pp. 560-562. ISSN: 1369-7056 CODEN: IDRUFN
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Conference Article; (Conference paper)
FILE SEGMENT: 029 Clinical and Experimental Biochemistry
030 Clinical and Experimental Pharmacology
031 Arthritis and Rheumatism
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English
ENTRY DATE: Entered STN: 24 Jul 2003
Last Updated on STN: 24 Jul 2003
AB Dr. Moss briefly summed up the conference by describing the growth in the development of kinase research over the years and the commitment being invested by companies aiming to find effective screening strategies. He closed the day by remarking on the new challenge for researchers of turning the concepts discussed into successful drugs.

L14 ANSWER 5 OF 5 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

ACCESSION NUMBER: 2003:501918 BIOSIS
DOCUMENT NUMBER: PREV200300498316
TITLE: Preclinical pharmacokinetics and metabolism of CHIR258, a potent tyrosine kinase inhibitor.
AUTHOR(S): Vora, Jayesh [Reprint Author]; Haroldsen, Peter [Reprint Author]; Renhowe, Paul [Reprint Author]; Heise, Carla [Reprint Author]; Steigerwalt, Ronald [Reprint Author]; Todd, Marque [Reprint Author]; Harris, Alex [Reprint Author]; Samara, Emil [Reprint Author]
CORPORATE SOURCE: Chiron Corporation, Emeryville, CA, USA

SOURCE: Proceedings of the American Association for Cancer Research Annual Meeting, (July 2003) Vol. 44, pp. 753. print.
Meeting Info.: 94th Annual Meeting of the American Association for Cancer Research. Washington, DC, USA. July 11-14, 2003.
ISSN: 0197-016X.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LANGUAGE: English
ENTRY DATE: Entered STN: 29 Oct 2003
Last Updated on STN: 29 Oct 2003

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	21.81	76.13

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.28

FILE 'STNGUIDE' ENTERED AT 16:53:40 ON 02 DEC 2009

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 27, 2009 (20091127/UP).

=> d his

(FILE 'HOME' ENTERED AT 16:47:45 ON 02 DEC 2009)

FILE 'REGISTRY' ENTERED AT 16:47:57 ON 02 DEC 2009
L1 1 S CHIR 258/CN
L2 31 S 405169-16-6/CRN

FILE 'CAPLUS' ENTERED AT 16:49:05 ON 02 DEC 2009
L3 64 S L2
L4 2 S L3 AND AD<20031107

FILE 'REGISTRY' ENTERED AT 16:49:48 ON 02 DEC 2009

FILE 'CAPLUS' ENTERED AT 16:49:49 ON 02 DEC 2009
L5 0 S 1000873-96-0/DR

FILE 'REGISTRY' ENTERED AT 16:50:24 ON 02 DEC 2009
L6 1 S 1000873-96-0/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 16:50:46 ON 02 DEC 2009
L7 63 S L6
L8 2 S L7 AND AD<20031107

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:51:43 ON 02 DEC 2009
L9 0 S L2

FILE 'REGISTRY' ENTERED AT 16:51:51 ON 02 DEC 2009
SET SMARTSELECT ON
L10 SEL L2 1- CHEM : 36 TERMS

```
                SET SMARTSELECT OFF

     FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:51:53 ON 02 DEC 2009
L11          107 S L10
L12           93 S L11 AND (?CANCER? OR ?TUMOR? OR ?TUMOUR? OR ?NEOPLASM?)
L13           87 DUP REM L12 (6 DUPLICATES REMOVED)
L14            5 S L13 AND PD<20031107

     FILE 'STNGUIDE' ENTERED AT 16:53:40 ON 02 DEC 2009

=>

---Logging off of STN---



=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.07      76.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                       0.00      -3.28

STN INTERNATIONAL LOGOFF AT 16:54:08 ON 02 DEC 2009
```